Acetyl Hexapeptide-8

What is Acetyl Hexapeptide-8?

A topical peptide marketed to soften expression wrinkles by modulating SNARE complex-mediated muscle contraction.

This profile is educational. It organizes publicly discussed research context for Acetyl Hexapeptide-8 and related naming aliases — it is not a treatment guide.

Proposed mechanism

Competitive inhibition of SNARE complex formation, reducing acetylcholine vesicle fusion and attenuating superficial muscle contraction (botox-like mechanism at cosmetic level).

Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.

Current research notes

Human evidence grade: Limited human evidence

Preclinical evidence grade: Moderate human evidence

Argireline is widely used in "botox-like" serums. In vitro and small clinical studies report wrinkle depth reduction. Effects are modest compared to neuromodulator injections. Human evidence is limited to cosmetic trials. Topical only in legitimate research contexts.

Key uncertainties

• Comparison with established wrinkle treatments

Research areas being studied

• Expression wrinkles
• Cosmetic neuromodulation

Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.

Safety & side-effect notes

Reported or discussed adverse effects

• Topical irritation rare

Additional risks & considerations

• Modest efficacy expectations
• Marketing overstatement

Regulatory status

Not FDA-approved

Cosmetic ingredient.

Regulatory framing here is educational and can lag policy changes. Check official sources for current status.

Frequently asked questions

References & sources

• Blanes-Mira C et al. (2002). Acetyl hexapeptide-3 in anti-wrinkle formulations — Int J Cosmet Sci. Evidence type: in_vitro.